A Phase IV Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-Valvular Atrial Fibrillation Undergoing Cardioversion

Trial Profile

A Phase IV Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-Valvular Atrial Fibrillation Undergoing Cardioversion

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Apixaban (Primary)
  • Indications Atrial fibrillation; Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMANATE
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Aug 2017 Results from this trial have been presented at the ESC Congress 2017, according to a Bristol-Myers Squibb media release.
    • 28 Aug 2017 Results published in a Bristol-Myers Squibb media release.
    • 18 Aug 2017 According to a Bristol-Myers Squibb media release, data from this study will be presented at the European Society of Cardiology (ESC) congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top